Navigation Links
Pexiganan Phase 3 Clinical Trials Results Published in December Issue of CID
Date:12/17/2008

Experts assess likelihood of use to treat mildly infected diabetic foot ulcers based upon data from randomized, controlled, double-blinded multi-center clinical trials of pexiganan cream

DALLAS, Dec. 17 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) and MACROCHEM CORPORATION (OTC Bulletin Board: MACM) announced today that the results of two Phase 3 studies of pexiganan for the topical treatment of mild diabetic foot infection were published in the December 15, 2008 issue of Clinical Infectious Diseases. The publication was authored by Benjamin A. Lipsky, M.D., Veteran's Affairs Puget Sound Healthcare System and the University of Washington School of Medicine, Seattle, WA; Kenneth J. Holroyd, M.D., Vanderbilt University School of Medicine, Nashville, TN; and Michael Zasloff, M.D., Georgetown University School of Medicine, Washington, D.C. The authors concluded that based on the data from these Phase 3 studies, topical pexiganan might be an effective alternative to oral antibiotic therapy in treating diabetic patients with a mildly infected foot ulcer, and might reduce the risk of selecting antimicrobial-resistant bacteria.

Overall, 835 patients were randomized; those in each treatment arm were similar with regard to dermographic and clinical characteristics. Although study 303 failed to demonstrate equivalence, study 304 and the combined data for the 2 trials demonstrated equivalent results (within the 95% confidence interval) for topical pexiganan and oral ofloxacin in clinical improvement rates (85%-90%), overall microbiological eradication rates (42%-47%), and wound healing rates. The incidence of worsening cellulitis (2%-4%) and amputation (2%-3%) did not differ significantly between treatment arms. Bacterial resistance to ofloxacin emerged in some patients who received ofloxacin, but no significant resistance to pexiganan emerged among patie
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
2. CRSTI and Medical City Hospital Dallas Currently Recruiting For a Phase 2 Clinical Trial of MYDICAR(R) for Advanced Heart Failure
3. Wyeth Announces Positive Data from Phase 2 Study of Neratinib in Advanced HER-2-Positive Breast Cancer
4. Celator(R) Pharmaceuticals Presents Phase 1 Results With CPX-351 in Patients With Advanced Leukemia at the American Society of Hematology Meeting
5. Promising trials of malaria vaccine lead to calls for Phase 3 development
6. Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
7. Phase 2 Results of Rigels R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
8. OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product
9. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
10. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
11. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Registration is now open for the ... 10K, 5K, and 1-mile walk/run to be held on ... Local 338 RWDSU/UFCW, the Town of Babylon, and Island ... of Babylon Town Hall in Lindenhurst, NY. Registration is ... is organized by Hope For The Warriors®, a national ...
(Date:9/16/2014)... Alabama (PRWEB) September 16, 2014 *To find ... AL, visit Achieve Clinical Research on the web ( http://www.achieveclinical.com/trial/pneumonia-vaccine/ ... those who qualify:, There is no ... , Compensation may be provided for time ... pneumonia and influenza are the eighth leading cause of death ...
(Date:9/16/2014)... *Anyone who is interested in learning ... FL can visit Avail Clinical Research on the web ... 785-2404. , Why Are Volunteers Needed? , The common ... infecting mankind. While infections may not be as deadly ... more annual visits to the doctor than any other ...
(Date:9/16/2014)... justthoughtyoushouldknow.org , popular current events, ... new site today. The new site is better ... information easier to find, ingest, and share. , ... easy-to-read pages the information that we believe any ... retired college professor and founder of the site. ...
(Date:9/16/2014)... September 16, 2014 BQuick Nutrition is ... of its most popular products - BQuick BURN Clarinol ... educate the general public about the many benefits of ... building lean muscle mass. As well as having a ... benefits, supplement facts, and nutritional information - making it ...
Breaking Medicine News(10 mins):Health News:The Hope For The Warriors Long Island Run For The Warriors to Honor Wounded and Families of the Fallen 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 2Health News:Avail Clinical Research Is Looking for Healthy Adults Who Are Interested in Participating in a Common Cold Clinical Trial near Orlando, Florida 3Health News:JustThoughtYouShouldKnow.org Debuts New Website 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 2Health News:BQuick Nutrition Announces Newly Branded BURN Clarinol CLA Powder 3
... be promising news in the quest to find a ... (ALS), or Lou Gehrigs disease, scientists at the University ... shown that targeting neuronal support cells called astrocytes sharply ... in the laboratory of Don Cleveland, Ph.D., UCSD Professor ...
... to prove anecdotes that canines can smell dangerous drops in ... Irish researchers hope to prove that a dog,s keen sense ... blood sugar levels of diabetics. , Canines have already shown ... helping the physically disabled with daily tasks. , But researchers ...
... found that the gene ENPP1 is linked to preterm ... , Errol Norwitz, M.D., associate professor in the Department ... present preliminary results from this research at the Society ... in Dallas, Texas. , One out of eight babies ...
... Survey says latent infections among immigrants, minorities, poor thwart ... -- It appears that the United States will fall ... according to an analysis of National Health and Nutritional ... of latent TB infection (LTBI) in the U.S. population ...
... February 2, 2008 One-year data from a second ... given every 12 weeks provided sustained, clinically meaningful improvement ... through one year. According to findings presented at ... 87 percent of patients responding to ustekinumab 45 mg ...
... 1 Kristin Davis, star,of US hit TV show ... leading AIDS,activists at a Johannesburg press conference tomorrow, Saturday, ... and AIDS epidemic in,South Africa., (Photo: http://www.newscom.com/cgi-bin/prnh/20080201/LAF106-a ... http://www.newscom.com/cgi-bin/prnh/20080201/LAF106-b ) Kristin, ...
Cached Medicine News:Health News:Targeting astrocytes slows disease progression in ALS 2Health News:Dogs Could Be a Diabetic's Best Friend 2Health News:Dogs Could Be a Diabetic's Best Friend 3Health News:Dogs Could Be a Diabetic's Best Friend 4Health News:Gene linked to preterm birth among Hispanic women 2Health News:U.S. Unlikely to Meet Target for TB Elimination 2Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 2Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 3Health News:Ustekinumab Phase 3 data show long-term improvement of chronic plaque psoriasis 4Health News:'Sex & the City' Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS 2Health News:'Sex & the City' Gets Serious About HIV and AIDS in South Africa - Kristin Davis Helps Oxfam Break the Stigma and Close the Treatment Gaps Fuelling AIDS 3
(Date:9/15/2014)... Quebec , Sept. 15, 2014  Valeant Pharmaceuticals ... announced that its wholly owned subsidiary, Valeant Pharmaceuticals International, ... principal amount of its 6.75% Senior Notes due 2017, ... October 15, 2014 and has mailed an irrevocable notice ... 15, 2014, a copy of the irrevocable notice of ...
(Date:9/15/2014)... DALLAS , Sept. 15, 2014 /PRNewswire-iReach/ -- MedicOne ... ambulance transport services, has been selected by Inc. ... companies in America. Photo - ... Inc. 500|5000 list identifies successful, privately-held companies with ... MedicOne Medical Response, one of only two ambulance ...
(Date:9/15/2014)... SINGAPORE , Sept. 15, 2014  Catalist-listed QT ... "the Group"), a developer and manufacturer of minimally invasive ... pleased to announce that the Group has enrolled the ... Germany . Multiple patients have already been ... , at Auckland City Hospital, in Auckland, ...
Breaking Medicine Technology:Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 2MedicOne Medical Response Named to 2014 Inc. 5000 Fastest Growing Companies List 3First European Patients Enrolled in QT Vascular's ENDURE Trial 2First European Patients Enrolled in QT Vascular's ENDURE Trial 3First European Patients Enrolled in QT Vascular's ENDURE Trial 4First European Patients Enrolled in QT Vascular's ENDURE Trial 5
... (Nasdaq: ISIS ), the leader in antisense therapeutics, today ... Adams, 2009 Cardiovascular Conference on Tuesday, November 10, 2009, at ... , A live audio webcast of the presentation will be ... Web site, www.isispharm.com . A replay ...
... WASHINGTON, Nov. 2 The owner and operator of ... guilty to defrauding the Medicare program, announced Assistant Attorney ... Attorney Tim Johnson of the Southern District of Texas ... of Health & Human Services (HHS). , Noel Wayne ...
Cached Medicine Technology:Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 2Medical Equipment Company Owner Pleads Guilty to Fraud Scheme Involving Nutritional Supplies and "Arthritis Kits" 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: